DEPOMED REPORTS RESULTS OF GLUMETZA TRIAL

Depomed has reported the results of a Phase III clinical trial with Glumetza, a once-daily version of metformin for the treatment of Type II diabetes.

The study showed that the drug was as effective as immediate-release metformin and was well-tolerated. The most effective result was observed with a once-daily 2,000 mg dose of Glumetza.